1. Nox4 genetic inhibition in experimental hypertension and metabolic syndrome
- Author
-
Hugues Jacob, Lola Madeira, Yann Herault, Guillaume Pavlovic, Marie-France Champy, Laurent Monassier, Lahcen El Fertak, Marie-Christine Birling, Ghina Bou-About, Tania Sorg, John S. Mudgett, Benoit Petit-Demoulière, Estelle Ayme-Dietrich, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de pharmacologie et de toxicologie neurocardiovasculaire (LPTNC), Université de Strasbourg (UNISTRA), CHU Strasbourg, Merck Research Laboratories, Institut Clinique de la Souris, and univOAK, Archive ouverte
- Subjects
0301 basic medicine ,Blood Glucose ,Male ,Time Factors ,Cardiac fibrosis ,Blood Pressure ,030204 cardiovascular system & hematology ,Angiotensin ,NADPH oxydase ,0302 clinical medicine ,Heart Rate ,Metabolic Syndrome ,Mice, Knockout ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Ventricular Remodeling ,Angiotensin II ,General Medicine ,Pulse pressure ,Angiotensine ,Phenotype ,NADPH Oxidase 4 ,Hypertension ,cardiovascular system ,Female ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Cardiomegaly ,Diet, High-Fat ,03 medical and health sciences ,Nox4 ,Métabolisme ,Internal medicine ,Diabetes mellitus ,Heart rate ,Renin–angiotensin system ,medicine ,Animals ,Genetic Predisposition to Disease ,Triglycerides ,NADPH oxidase ,business.industry ,Myocardium ,medicine.disease ,Fibrosis ,Mice, Inbred C57BL ,Disease Models, Animal ,030104 developmental biology ,Endocrinology ,Blood pressure ,Metabolism ,Heart failure ,Metabolic syndrome ,business ,Reactive Oxygen Species ,Biomarkers ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Summary Background Metabolic syndrome is a combination of symptoms including obesity, dyslipidaemia, glucose intolerance and hypertension. Oxidative stress appears to be a pathophysiological factor that links these signs and encourages progression towards heart failure and diabetes. Nox4 is a hydrogen peroxide nicotinamide adenine dinucleotide phosphate (NADPH) oxidase isoform – found in various cardiovascular cells and tissues, but also in tissues such as the liver – which is involved in glucose and lipid homeostasis. Aims To test whether inhibition of the Nox4 enzyme could improve blood pressure and metabolic parameters in mice receiving either angiotensin II or a high-fat diet. Methods Systolic and diastolic arterial pressures, pulse rate and heart rate were obtained in 24 male mice (12 wild-type [WT] and 12 Nox4–/–) before and during 14 days of angiotensin II infusion. After angiotensin II infusion, cardiac histological remodeling was assessed. Weight and biochemical parameters were measured in 18 male and 18 female mice (nine WT and nine Nox4–/– per gender) after 10 weeks on a standard chow diet, then 15 weeks on a high-fat diet. Glucose tolerance and insulin sensitivity were tested at age 25 weeks. Results Knock-out animals did not demonstrate a baseline blood pressure phenotype, but blocking Nox4 protected against angiotensin II-mediated arterial and pulse pressure increases. No protection against angiotensin II-induced cardiac fibrosis was observed. From a metabolic point of view, Nox4 inhibition reduced plasma triglycerides in male and female mice under a chow diet. However, Nox4 deletion did not affect the metabolic profile under a high-fat diet in males or females, but increased glucose intolerance in females. Conclusion Our data identify Nox4 as a key source of radical oxygen species involved in hypertension and some metabolic problems.
- Published
- 2017
- Full Text
- View/download PDF